Assessment of SnFe2O4 nanoparticles for potential application in theranostics: Synthesis, characterization, in vitro, and in vivo toxicity

In this research, tin ferrite (SnFe2O4 ) NPs were synthesized via hydrothermal route using ferric chloride and tin chloride as precursors and were then characterized in terms of morphology and structure using Fourier-transform infrared spectroscopy (FTIR), Ultraviolet–visible spectroscopy (UV-Vis), X-ray power diffraction (XRD), Scanning electron microscopy (SEM), Transmission electron microscopy (TEM), and Brunauer–Emmett–Teller (BET) method. The obtained UV-Vis spectra was used to measure band gap energy of as-prepared SnFe2O4 NPs. XRD confirmed the spinel structure of NPs, while SEM and TEM analyses disclosed the size of NPs in the range of 15–50 nm and revealed the spherical shape of NPs. Moreover, energy dispersive X-ray spectroscopy (EDS) and BET analysis was carried out to estimate elemental composition and specific surface area, respectively. In vitro cytotoxicity of the synthesized NPs were studied on normal (HUVEC, HEK293) and cancerous (A549) human cell lines. HUVEC cells were resistant to SnFe2O4 NPs; while a significant decrease in the viability of HEK293 cells was observed when treated with higher concentrations of SnFe2O4 NPs. Furthermore, SnFe2O4 NPs induced dramatic cytotoxicity against A549 cells. For in vivo study, rats received SnFe2O4 NPs at dosages of 0, 0.1, 1, and 10 mg/kg. The 10 mg/kg dose increased serum blood urea nitrogen and creatinine compared to the controls (P < 0.05). The pathology showed necrosis in the liver, heart, and lungs, and the greatest damages were related to the kidneys. Overall, the in vivo and in vitro experiments showed that SnFe2O4 NPs at high doses had toxic effects on lung, liver and kidney cells without inducing toxicity to HUVECs. Further studies are warranted to fully elucidate the side effects of SnFe2O4 NPs for their application in theranostics

In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes

In this study, paclitaxel (PTX)-loaded pH-responsive niosomes modified with ergosterol were developed. This new formulation was characterized in terms of size, morphology, encapsulation efficiency (EE), and in vitro release at pH 5.2 and 7.4. The in vitro efficacy of free PTX and niosome/PTX was assessed using MCF7, Hela, and HUVEC cell lines. In order to evaluate the in vivo efficacy of niosomal PTX in rats as compared to free PTX, the animals were intraperitoneally administered with 2.5 mg/kg and 5 mg/kg niosomal PTX for two weeks. Results showed that the pH-responsive niosomes had a nanometric size, spherical morphology, 77% EE, and pH-responsive release in pH 5.2 and 7.4. Compared with free PTX, we found markedly lower IC50s when cancer cells were treated for 48 h with niosomal PTX, which also showed high efficacy against human cancers derived from cervix and breast tumors. Moreover, niosomal PTX induced evident morphological changes in these cell lines. In vivo administration of free PTX at the dose of 2.5 mg/kg significantly increased serum biochemical parameters and liver lipid peroxidation in rats compared to the control rats. The situation was different when niosomal PTX was administered to the rats: the 5 mg/kg dosage of niosomal PTX significantly increased serum biochemical parameters, but the group treated with the 2.5 mg/kg dose of niosomal PTX showed fewer toxic effects than the group treated with free PTX at the same dosage. Overall, our results provide proof of concept for encapsulating PTX in niosomal formulation to enhance its therapeutic efficacy. [Figure not available: see fulltext.

F127/cisplatin microemulsions: In vitro, in vivo and computational studies

The development of effective strategies for local administration of chemotherapeutic drugs, thus minimizing the adverse side effects to patients, is one of the key challenges in biomedicine and cancer research. This work reports the formulation and characterization of PluronicF127 microemulsions to enhance the bioavailability of Cisplatin (Cis). The size of Cis microemulsion was about 12.0 nm, as assessed by dynamic light scattering analysis. In vitro cytotoxic activity of free Cis and F127/Cis microemulsions were studied on malignant (C152 and MCF7) and normal (HUVEC) cells via tetrazolium (MTT) colorimetric assay. Cell morphology was also monitored. In vitro assessments revealed thatF127/Cis microemulsions induced cytotoxicity/morphological changes to a lesser extent than free Cis. Regarding in vivo experiments, F127/Cis microemulsions were injected intraperitoneally at 7 and 14 mg/kg doses into adult male Wistar rats to assess histologic and biochemical changes. In this case, the bulk Cis group caused severe histopathological changes and significant increases in serum liver enzymes and serum kidney function markers. The group treated with the 14 mg/kg dose of F127/Cis microemulsions also showed severe fatty changes and significant increases in serum liver enzymes, blood urea nitrogen, and creatinine levels. The group treated with the low dose of nano-Cis showed a significant increase in serum liver enzymes levels accompanied by mild fatty changes of the liver. Theoretical surveys were performed to get an understanding of the interplay between F127 and Cis. Results reveal that hydrogen bonding (HB) interactions with F127have an influence on the molecular properties of Cis and may playa role in the lower toxicity of F127/Cis in comparison to free Cis

Nanomaterials for the diagnosis and treatment of head and neck cancers: A review

Head and neck cancer (HNC) is a category of cancers that typically arise from the nose-, mouth-, and throat-lining squamous cells. The later stage of HNC diagnosis significantly affects the patient’s survival rate. This makes it mandatory to diagnose this cancer with a suitable biomarker and imaging techniques at the earlier stages of growth. There are limitations to traditional technologies for early detection of HNC. Furthermore, the use of nanocarriers for delivering chemo-, radio-, and phototherapeutic drugs represents a promising approach for improving the outcome of HNC treatments. Several studies with nanostructures focus on the development of a targeted and sustained release of anticancer molecules with reduced side effects. Besides, nanovehicles could allow co-delivering of anticancer drugs for synergistic activity to counteract chemo-or radioresistance. Additionally, a new generation of smart nanomaterials with stimuli-responsive properties have been developed to distinguish between unique tumor conditions and healthy tissue. In this light, the present article reviews the mechanisms used by different nanostructures (metallic and metal oxide nanoparticles, polymeric nanoparticles, quantum dots, liposomes, nanomicelles, etc.) to improve cancer diagnosis and treatment, provides an up-to-date picture of the state of the art in this field, and highlights the major challenges for future improvements

Biochemical, ameliorative and cytotoxic effects of newly synthesized curcumin microemulsions: Evidence from in vitro and in vivo studies

Curcumin is known to exhibit antioxidant and tissue-healing properties and has recently attracted the attention of the biomedical community for potential use in advanced therapies. This work reports the formulation and characterization of oil-in-water F127 microemulsions to enhance the bioavailability of curcumin Microemulsions showed a high encapsulation efficiency and prolonged release. To investigate the interactions of curcumin with one unit of the polymeric chain of surfactant F127, ethyl butyrate, and sodium octanoate, as well as the interaction between ethyl butyrate and one unit of the F127 polymer chain, the Density Functional Theory (DFT) calculations at the M06-2X level of theory, were performed in water solution. The MTT assay was used to assess the cytotoxicity of free and encapsulated curcumin on non-malignant and malignant cell lines. Combination effects were calculated according to Chou-Talalay’s principles. Results of in vitro studies indicated that MCF7 and HepG2 cells were more sensitive to curcumin microemulsions. Moreover, a synergistic relationship was observed between curcumin microemulsions and cisplatin in all affected fractions of MCF7 and HepG2 cells (CI < 0.9). For in vivo investigation, thioacetamide-intoxicated rats received thioacetamide (100 mg/kg Sc) followed by curcumin microemulsions (30 mg/kg Ip). Thioacetamideintoxicated rats showed elevated serum liver enzymes, blood urea nitrogen (BUN), and creatinine levels, and a significant reduction in liver superoxide dismutase (SOD) and catalase (CAT) activities (p < 0.05). Curcumin microemulsions reduced liver enzymes and serum creatinine and increased the activity of antioxidant enzymes in thioacetamide-treated rats in comparison to the untreated thioacetamide-intoxicated group. Histopathological investigations confirmed the biochemical findings. Overall, the current results showed the desirable hepatoprotective, nephroprotective, and anti-cancer effects of curcumin microemulsions

CoNi alloy nanoparticles for cancer theranostics: synthesis, physical characterization, in vitro and in vivo studies

Nanomaterials are attracting increasing interest in many biomedical fields, including the fight against cancer. In this context, we successfully synthesized CoNi alloy nanoparticles (NPs) by a simple polyol process. The magnetic characteristics of the products were measured by vibration sample magnometry, which revealed that the samples have soft ferromagnetic behavior. The microstructure and morphology were inspected by X-ray diffraction and scanning electron microscopy, respectively. Human cancer cells derived from the breast (MCF7) and oral cavity (C152) and normal cells derived from human umbilical vein endothelial cells (HUVECs) were treated with increasing concentrations of CoNi NPs, and their cytotoxic effect was measured via MTT and lactate dehydrogenase (LDH) leakage assays. We found that treatments by using 12.5 to 400 µg/mL of Co0.5Ni0.5, Co0.6Ni0.4, and Co0.4Ni0.6 NPs were associated with significant concentration-dependent toxicity toward such cell lines and profoundly enhanced LDH leakage following 48 h of exposure (P < 0.05 compared with untreated cells). Besides, a NP dose of 6.25 µg/mL did not affect the survival of HUVECs while leading to marked cell death in MCF7 and C152 cells. In vivo experiments in rats were done to investigate the biochemical and histopathological changes over three weeks, following intraperitoneal administration of Co0.5Ni0.5, Co0.6Ni0.4, and Co0.4Ni0.6 NPs (100 mg/kg). As compared with the controls, the exposure to NPs caused significant elevations in aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, serum creatinine, serum catalase activity, serum superoxide dismutase, and liver malondialdehyde levels. Also, rats treated with Co0.6Ni0.4 NPs showed more severe histopathological changes of the liver and kidney. Our findings represent an essential step toward developing theranostic nanoplatforms for selective cancer treatment

Emerging Nano-Theranostic Strategies against Non-Alcoholic Fatty Liver Disease: a review

As a major global cause of liver damage, non-alcoholic fatty liver disease (NAFLD) is associated with excessive hepatocellular accumulation of lipids in the liver, elevated levels of hepatic enzymes,and the fibrotic evidence. The primary therapies for NAFLD are changing lifestyle or managing comorbid-associated diseases. Lately, nanotechnology has revolutionized the art of nanostructure synthesis for disease imaging, diagnosis, and treatment. Loading drugs into nanocarriers hasbeen established as a promising strategy to extend their circulating time, particularly in treating NAFLD. In addition, considering a master modulator of adipogenesis and lysosomal biogenesis and function, designing novel nanostructures for biomedical applications requires using biodegradable materials. Various nanostructures, including inorganic nanoparticles (NPs), organic-based NPs, metallic nanocarriers, biodegradable polymeric nanocarriers, polymer-hybrid nanocarriers, and lipid-based nanocarriers have been designed for NAFLD treatment, which significantly affected serum glucose/lipid levels and liver function indices. NPs modified with polymers, bimetallic NPs, and superparamagnetic NPs have been used to design sensitive nanosensors to measure NAFLD-related biomarkers. However, certain limitations are associated with their use as diagnostic agents. The purpose of this review article is to shed light on the recent advancements in the field of nanomedicine for the early diagnosis, treatment, and prognosis of this progressive liver disease

Application of Nanobiotechnology for Early Diagnosis of SARS-CoV-2 Infection in the COVID-19 Pandemic

Abstract: A most discussed topic of the new decade, COVID-19 is an infectious disease caused by the recently discovered SARS-CoV-2. With an exceedingly high transmission rate, COVID-19 has affected almost all the countries in the world. Absent any vaccine or specific treatment, the humanity is left with nothing but the legacy method of quarantine. However, quarantine can only be effective when combined with early diagnosis of suspected cases. With their high sensitivity and unmatched specificity, biosensors have become an area of interest for development of novel diagnostic methods. Compared to the more traditional diagnostics, nanobiotechnology introduces biosensors as different diagnostics with greater versatility in application. Today, a growing number of analytes are being accurately identified by these nanoscopic sensing machines. Several reports of validated application with real samples further strengthen this idea. As of recent, there has been a rise in the number of studies on portable biosensors. Despite the slow progression, certain devices with embedded biosensors have managed to be of diagnostic value in several countries. The perceptible increase in development of mobile platforms has revolutionized the healthcare delivery system in the new millennium. The present article reviews the most recent advancements in development of diagnostic nanobiosensors and their application in the clinical fields. Key points: � There is no specific treatment for highly transmissible SARS-CoV-2. � Early diagnosis is critical for control of pandemic. � Highly sensitive/specific nanobiosensors are emerging assets against COVID-19. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature

Chitosan/polyvinyl alcohol nanofibrous membranes: towards green super-adsorbents for toxic gases

Removal of hazardous gases from the atmosphere has become a big challenge for scientists and engineers alike. Eco-friendly nature of biopolymers has given a new dimension to the debate within the environmental science area but attempts mainly failed to cleanse the air stream of toxic gases as a consequence of design imperfections. In this work, green electrospun nanofibrous membranes based on chitosan (Cs)/polyvinyl alcohol (PVA) composite with a very high carbon monoxide adsorption capacity (much higher than the values one may expect from activated carbon and zeolite adsorbents, and also higher than that of the metal-organic framework) are developed. 2 k�1 factorial design, response surface and desirability function analyses are merged to optimize the electrospinning parameters for functional-based carbon monoxide elimination. The best Cs/PVA adsorbent obtained through multi-objective optimization has a very high desirability value level of 0.953. Optimized electrospinning parameters are: Voltage = 17 kV, spinning distance = 13 cm, flow rate = 0.2 mL/h, and PVA concentration = 6 wt.; and optimized properties are: maximum thermal stability = 329 °C, minimum fiber diameter = 9.8 nm, and maximum surface area = 2204 m 2 /g. This work opens a new era for taking the next steps towards the design and optimization of green super-adsorbents for gaseous contaminations. © 201

Частота возникновения и факторы риска развития хронического отторжения при остром отторжении трансплантированной печени у детей

Background. Chronic graft rejection (CR) represents an increasing concern in pediatric liver transplantation (LT). Risk factors of CR in this population are uncertain. In present study, we aimed to ascertain if clinical parameters could predict the occurrence of CR in LT children.Methods. We retrospectively analyzed the results from 47 children who had experienced acute hepatic rejection in Namazee hospital, Shiraz, Iran during 2007–2017.Results. Out of 47 children, 22 (46.8%) and 25 (53.2%) were boys and girls respectively. Ascites, gastrointestinal bleeding, and spontaneous bacterial peritonitis were observed in 20 (44.4%), 14 (31.1%), and 4 (9.1%) respectively. Posttransplant vascular and biliary complications were observed in 3 (7%) and 4 (9.3%) cases respectively. The mean time from LT to normalization of liver enzymes was 14.2 ± 7.5 days. The mean of acute rejection episodes was 1.4 ± 0.6 (median = 1 (22, 46.8%), range of 1–3). Six (12.7%) patients experienced CR. The mean time from LT to CR was 75 ± 28.4 days. A significant association was found between CR and patients’ condition (being inpatient or outpatient) before surgery (P = 0.03). No significant relationship was found between CR and post-transplant parameters except for biliary complications (P = 0.01). Both biliary complication (RR = 33.7, 95% CI: 2.2–511, P = 0.01) and inpatient status (RR = 10.9, 95% CI: 1.1–102.5, P = 0.03) significantly increased the risk of CR.Conclusion. Being hospitalized at the time of LT, and development of biliary complications might predict risk factors for development of CR in LT children.Актуальность. Хроническое отторжение (ХО) трансплантата становится все более серьезной проблемой при трансплантации печени (ТП) у детей. Факторы риска ХО в этой популяции остаются неопределенными. В настоящем исследовании мы стремились выяснить, можно ли спрогнозировать возникновение ХО у детей с ТП по клиническим параметрам.Методы. Мы провели ретроспективный анализ 47 случаев острого отторжения трансплантата печени у детей, прооперированных в больнице Намази (г. Шираз, Иран) в период с 2007-го по 2017 год.Результаты. В исследование включили 47 детей: 22 (46,8%) мальчика и 25 (53,2%) девочек. Асцит, желудочно-кишечное кровотечение и спонтанный бактериальный перитонит наблюдались в 20 (44,4%), 14 (31,1%) и 4 (9,1%) случаях соответственно. Посттрансплантационные сосудистые и билиарные осложнения отмечались в 3 (7%) и 4 (9,3%) случаях соответственно. Показатели печеночных ферментов нормализовались в среднем через 14,2 ± 7,5 дня после ТП. Среднее количество эпизодов острого отторжения составило 1,4 ± 0,6 (медиана = 1 (22; 46,8%), диапазон 1–3). У 6 (12,7%) пациентов наблюдалось ХО. Среднее время от ТП до ХО составило 75 ± 28,4 дня. Мы выявили статистически значимую корреляцию между ХО и предоперационным периодом (нахождение в стационаре или амбулаторная подготовка, р = 0,03). ХО статистически значимо коррелировало с наличием билиарных осложнений (р = 0,01), другие послеоперационные факторы статистически значимо на него не влияли. Билиарные осложнения (ОР = 33,7, 95% ДИ 2,2–511, р = 0,01) и предоперационный статус пациента (ОР = 10,9, 95% ДИ 1,1–102,5, р = 0,03) значительно повышали риск ХО.Заключение. Госпитализация при подготовке к трансплантации и раннее выявление билиарных осложнений могут предотвратить развитие ХО трансплантата у детей после ТП